VeinWay Ltd.

VeinWay’s mission is to improve access to healthcare for patients suffering from chronic venous diseases. VeinWay is addressing the largest clinical unmet need facing interventional radiology, chronic venous blockages. Current vein crossing procedures are challenging, time consuming, and failure prone. Even successful procedures typically require multiple tools resulting in high costs for the hospital.
 
VeinWay’s Traversa was developed specifically to enable physicians to cross these chronic blockages safely, easily, and quickly in the veins. Traversa has already helped physicians achieve success in seven compassionate use cases and a clinical trial is currently being planned for August 2024. The company has submitted it’s IDE to the FDA and is engaged in a series A round.